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NMDA receptors (NMDARs) play a critical role in neurotransmission, acting as essential
mediators of many forms of synaptic plasticity, and also modulating aspects of
development, synaptic transmission and cell death. NMDAR-induced responses are
dependent on a range of factors including subunit composition and receptor location.
Tissue-type plasminogen activator (tPA) is a serine protease that has been reported to
interact with NMDARs and modulate NMDAR activity. In this study we report that tPA
inhibits NMDAR-mediated changes in intracellular calcium levels in cultures of primary
hippocampal neurons stimulated by low (5 µM) but not high (50 µM) concentrations of
NMDA. tPA also inhibited changes in calcium levels stimulated by presynaptic release
of glutamate following treatment with bicucculine/4-aminopyridine (4-AP). Inhibition was
dependent on the proteolytic activity of tPA but was unaffected by α2-antiplasmin, an
inhibitor of the tPA substrate plasmin, and receptor-associated protein (RAP), a pan-
ligand blocker of the low-density lipoprotein receptor, two proteins previously reported
to modulate NMDAR activity. These findings suggest that tPA can modulate changes
in intracellular calcium levels in a subset of NMDARs expressed in cultured embryonic
hippocampal neurons through a mechanism that involves the proteolytic activity of tPA
and synaptic NMDARs.
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Introduction
NMDA receptors (NMDARs) play an essential role in the regulation of synaptic strength in the
brain (Lau and Zukin, 2007; Traynelis et al., 2010; Paoletti, 2011). These gated cation channels
are activated by the excitatory neurotransmitter glutamate and are essential mediators of brain
plasticity, impacting synaptic structure and function. NMDA receptor activation leads to rapid
alterations in synaptic strength that contribute to long-term potentiation (LTP) and long-term
depression as well as longer term changes that are important for maintaining neuronal network
function. Stimulation of NMDARs leads to activation of calcium-dependent signaling pathways
and changes in expression of plasticity-related genes. It is becoming increasingly clear that
these signaling properties are dependent on receptor localization and subunit composition.
NMDARs are mobile and move laterally between synaptic and extrasynaptic pools (Lau and Zukin,
2007; Bard and Groc, 2011). Synaptic and extrasynaptic receptors can stimulate different signaling
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pathways resulting in different neuronal responses. These may be
mediated by differences in NMDA receptor subunit composition
at the different sites, enabling synaptic and extrasynaptic
receptors to associate with different signalingmolecules (Rao and
Finkbeiner, 2007). NMDARs form tetrameric complexes. The
subunit composition of these complexes is diverse and plastic,
resulting in a large number of receptor subtypes that varies
during development and at adult synapses (Paoletti, 2011).
Tissue-type plasminogen activator (tPA) is a member of the
serine protease family most well known for its role in vascular
thrombolysis where it activates the zymogen plasminogen to
form plasmin, which degrades fibrin and remove blood clots
(Cesarman-Maus and Hajjar, 2005). tPA has been identified
in both the developing and adult nervous system where a
number of distinct roles have been proposed (Sappino et al.,
1993; Friedman and Seeds, 1994; Ware et al., 1995; Teesalu
et al., 2004). tPA is released from neurons following membrane
depolarization (Lochner et al., 2006) and regulates LTP and
synaptic plasticity. A genetic deficiency of tPA or inhibition of
tPA activity leads to a loss of LTP (Frey et al., 1996; Huang
et al., 1996; Calabresi et al., 2000) while overexpression of
tPA or addition of recombinant tPA leads to prolonged LTP
(Baranes et al., 1998; Madani et al., 1999). These and other
observations are consistent with roles for tPA in learning and
memory (Centonze et al., 2002; Pawlak and Strickland, 2002;
Fernández-Monreal et al., 2004b; Benchenane et al., 2007).
Several mechanisms may underpin these effects. At the cellular
level tPA has been linked to the formation of perforated synapses
(Neuhoff et al., 1999) and presynaptic varicosities (Baranes
et al., 1998) as well as changes in dendritic spines (Mataga
et al., 2004; Pawlak et al., 2005). Mechanistically, the proposed
roles for tPA in synaptic plasticity mainly focus on changes in
the proteolytic microenvironment impacting the remodeling of
extracellular matrix (Wu et al., 2000; Bukhari et al., 2011) and
synaptic connectivity, including cleavage of neurotrophins (Pang
et al., 2004; Barnes and Thomas, 2008) and neurotransmitter
receptors (Samson et al., 2008a; Macrez et al., 2010; Ng et al.,
2012).
In this study we have investigated the effects of tPA
on NMDA-mediated changes in intracellular calcium levels
using a primary embryonic rat hippocampal culture model
(Banker and Cowan, 1977). Calcium flux was stimulated
directly with varying concentrations of the glutamate receptor
agonist NMDA. We also stimulated presynaptic release of
glutamate using a γ-aminobutyric acid A (GABAA) receptor
antagonist and potassium channel blocker, 4-aminopyridine
(4-AP; Hardingham et al., 2002). Possible roles for plasmin and
low density lipoprotein receptor-related protein 1 (LRP-1), an
endocytic and signaling receptor that interacts with tPA (Zhuo
et al., 2000) were also examined.
Materials and Methods
Materials
Recombinant human tPA (Actilyser) was a generous gift from
Boehringer Ingelheim (Auckland, New Zealand) or purchased
from Biopur (Reinach, Switzerland). For some experiments
the excipients in Actilyser tPA were removed by dialysis
against HEPES (Samson et al., 2008b). NMDA, MK-801 and
amino-5-phosphonovalerate (APV) were purchased from Sigma
Aldrich (Auckland, New Zealand). Nimodipine, bicuculline
and 4-AP were purchased from Tocris (MO, USA). 2,7-Bis-
(4-aminobenzylidene)-cycloheptan-1-one dihydrochloride
(tPA-STOP) was purchased from American Diagnostica
(Greenwich, CT, USA). Human α2-antiplasmin was purchased
from MyBioSource (San Diego, CA, USA). Receptor-associated
protein (RAP) was produced as a glutathione S-transferase fusion
protein and purified by glutathione-affinity chromatography.
The glutathione S-transferase tag was removed by thrombin
cleavage prior to use. The active site mutant human tPA (S478A)
was purchased fromMolecular Innovations (MI, USA).
Primary Cell Culture
The use of animals in this research was approved by the
University of Auckland Animal Ethics Committee. Primary
hippocampal cultures were prepared from embryonic (E18)
Wistar rats as described previously (Borges et al., 2010; Lee
et al., 2015). Briefly, dissected hippocampi were dissociated
using papain and plated at 20,000 cells/well in clear-bottom,
black-walled 96-well amine plates (BD Biosciences, Auckland,
New Zealand). Cultures were maintained for 14–17 days
in vitro, in Neurobasal medium containing 1 × B27 and
1 × Glutamax (all from Invitrogen, Carlsbad, CA, USA), with
half medium changes 24 h following plating and then at 7 day
intervals.
Calcium Assays
All experiments were performed on cultures maintained
for 14–17 days in vitro. Cells were loaded with Fluo-
4 AM (Life Technologies) according to the manufacturer’s
instructions. Calcium responses were recorded on an Envision
plate reader (Perkin Elmer, MA, USA) using the following
settings: excitation filter, FITC 485 nm; emission filter,
520 nm. Each well was recorded individually, with 15 s
of baseline recording, followed by injection of agonist and
recording of the response for a further 45 s. Antagonists
were added manually 5 min (tPA) or 15 min (MK-801,
APV, nimodipine, tPA-STOP, α2-antiplasmin, RAP), prior to
recording. Raw fluorescence data were converted to ∆F/F0;
where F0 is the average fluorescence over the first 15 s of
recording prior to addition of agonist (baseline) and ∆F is
Fmax−F0.
Statistics
The area under the curve (AUC) from 0 to 45 s was
determined and used as the dependent variable for all statistical
analyses. These data were first transformed using a square root
transform to ensure that there was homogeneity of variance
and an approximately normal distribution of residuals in the
fitted statistical models. The data for all NMDA treatments
were analyzed as a complete set. This data set contained 24
individual plates of cells, 121 treatment by plate biological
replicates and 351 individual data points. The data for the
bicuculline and 4-AP treatments were analyzed separately,
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consisting of 4 plates of cells, 19 treatment by plate replicates
and 53 individual data points. Statistical analysis was conducted
in R 3.0.2 (R Development Core Team, 2013) using linear
mixed models of the transformed data. Data were modeled
with a one-factor randomized block design containing a fixed
effect for treatment and each plate considered a block. This
ensured that each experimental unit (block) was a replicate
plate of cells, with the technical replicates within a plate
functioning as sampling units. As the data contained a
nested structure (technical replicates nested within biological
replicates) and were not balanced (not all treatments were
in all plates, differing number of technical replicates), the
mixed models were fitted by restricted maximum likelihood
(REML) instead of general linear model/ANOVA (Littell et al.,
2002; Lazic, 2010). The statistical model equation (Littell et al.,
2002) was yijk = µ+ αi + bj + (αb)ij + eijk where yijk is the
transformed AUC measurement for the kth technical replicate
for treatment i in plate j, µ + αi is the mean transformed
AUC measurement for treatment i, bj is the random effect
associated with plate j, (αb)ij is the plate by treatment random
effect (biological replicates) and eijk is the random error
associated with technical replicate k for treatment i in plate j.
The R command lmer from the package lme4 (Bates et al.,
2013) was used to fit the linear mixed models using the
following model specification: transformed_AUC∼ treatment +
(1|plate_id)+ (1|plate_id:treatment). All statistical tests were
planned comparisons between a treatment and the appropriate
control and were calculated as contrasts from the fitted models
with p-values obtained using degrees of freedom determined
by the Kenward-Roger method using packages lsmeans (Lenth,
2013) and pbkrtest (Højsgaard, 2014). As these were decided
a priori no correction for multiple tests was applied (Ruxton and
Beauchamp, 2008). Data are plotted as backtransformed means
and SEM.
Results
tPA Inhibits the Calcium Response of
Hippocampal Neurons Activated with Low
but not High Concentrations of NMDA
To study the effect of recombinant tPA on NMDA-mediated
calcium flux, intracellular calcium levels were monitored in
embryonic hippocampal neurons cultured between 14 and
17 DIV (days in vitro), using a Fluo-4-based calcium assay
and a high speed fluorometric plate reader. Treatment with
the NMDAR agonist NMDA alone (5–100 µM) resulted in
a rapid and concentration-dependent increase in intracellular
calcium levels (Figures 1A,B). The fluorescent profiles indicated
differences in handling between lower (<10 µM) and higher
(>10 µM) concentrations of NMDA. Both responses were
characterized by a rapid influx of calcium (the amplitude
of which was concentration-dependent) which in the former
gradually returned towards baseline, but in the latter plateaued,
resulting in sustained calcium levels. In some instances small
oscillations were observed at the lower NMDA concentrations.
To investigate the effect of tPA on the calcium response,
FIGURE 1 | Tissue-type plasminogen activator (tPA) inhibits increases
in intracellular calcium in cultured rat hippocampal neurons stimulated
with low (5 µM) but not high (50 µM) concentrations of NMDA.
(A) Baseline Fluo-4 fluorescence was monitored in hippocampal cultures for
15 s prior to the addition of NMDA, at time = 0, to final concentrations ranging
between 5 and 100 µM. Fluo-4 fluorescence was monitored for a further 45 s.
Raw fluorescence values were converted to ∆F/F0, where F0 is the average
fluorescence over the first 15 s of recording prior to addition of agonist
(baseline) and ∆F is Fmax−F0. (B) The responses in A were quantitated by
measuring the area under the curve (AUC) and are presented relative to the
AUC for 5 µM NMDA (100%). Results are from three independent
experiments. Error bar, SEM. (C,D) Hippocampal cultures were preincubated
with tPA (40 µg/ml) for 5 min and Fluo-4 fluorescence monitored before and
after addition of NMDA to a final concentration of 50 µM. Data was collected
as in A and quantitated as in B. n.s, not significant. (E) Hippocampal cultures
were preincubated with tPA (40 µg/ml) for 5 min and Fluo-4 fluorescence
monitored before and after addition of NMDA to a final concentration of 5 µM.
(F) Quantitation of responses to tPA (Actilyse, sourced from Boehringer
Ingelheim), rtPA (rtPA sourced from Biopur) and dtPA (dialysed Actilyse). RFU,
Relative Fluorescent Units, ∗∗∗p < 0.001. Error bar, SEM.
Fluo-4-loaded neurons were treated with tPA. Addition of
tPA alone (40 µg/ml) did not produce any detectable
change in Fluo-4 fluorescence (Supplementary Figure 1) and
the calcium response to 50 µM NMDA was unaffected
by pre-incubation with tPA (Figures 1C,D). However, the
calcium response to 5 µM NMDA was significantly reduced
to 38 ± 8% of control (Figures 1E,F). The tPA used
in these experiments (Actilyser) contains a number of
excipients, including L-arginine, which has been suggested
to be toxic to neurons (Oh et al., 2005; Samson et al.,
2008b). To examine for any effects of the excipients in the
Actilyser tPA on the calcium response we repeated the
experiments with a dialysed preparation of Actilyser tPA
(dtPA) and a second commercial recombinant tPA, Biopur
tPA, which does not contain excipients. Both produced
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similar inhibition of the 5 µM NMDA-mediated calcium
response (Figure 1F), supporting the designation of tPA as
the active agent. For all subsequent experiments Actilyser
tPA, which will be referred to from now simply as tPA, was
used.
tPA Modulates Trans-Synaptic Stimulation
of NMDA Receptors
To investigate the NMDAR responses in more detail we assessed
the effects of glutamate and calcium channel antagonists on
tPA-sensitive calcium flux. The selective competitive NMDAR
antagonist APV (50 µM) and the use-dependent NMDAR
open channel blocker MK-801 (10 µM) both significantly
inhibited the calcium response of neurons treated with 50 µM
NMDA while the L-type voltage-gated calcium channel blocker
nimodipine (10 µM) had no significant effect on calcium
levels (Figures 2A–D). The calcium response of hippocampal
neurons to 5 µM NMDA was also blocked by APV and MK-
801. However, in contrast to stimulation with 50 µM NMDA,
nimodipine also inhibited the response (Figures 2E–H). These
results are consistent with previously published data (Jensen and
Wang, 1996; Soriano et al., 2006) and support trans-synaptic
activation of the postsynaptic cell by glutamate at 5 µMNMDA,
and direct stimulation of postsynaptic NMDARs at 50 µM
NMDA. We further investigated an effect of tPA on the calcium
response stimulated by presynaptic release of glutamate using
the GABAA receptor antagonist bicuculline (50 µM) and the
potassium channel blocker 4-AP (250 µM; Hardingham et al.,
2001b). Treatment resulted in synchronous spontaneous calcium
oscillations suggestive of synaptic coupling between neurons
(Figures 3A–C). These oscillations were markedly reduced
by MK-801 and nimodipine (Figures 3A–C,D). Importantly,
the calcium oscillations were also markedly inhibited by tPA
(Figure 3D).
The Proteolytic Activity of tPA is Required for its
Inhibitory Effect on NMDA-Mediated Changes in
Intracellular Calcium Levels
As proteolytic and non-proteolytic mechanisms have been
reported to modulate NMDA-mediated calcium levels, we tested
the effects of tPA-STOP, a reversible competitive inhibitor of
trypsin-like serine proteases, as well as an enzymatically inactive
tPA mutant. Unexpectedly, preincubation of cultures with
1 µM tPA-STOP alone almost completely inhibited intracellular
calcium changes activated by 5 µM NMDA (Supplementary
Figure 2). This result suggested an off-target effect of tPA-STOP
and so it was not used in any further experiments. In a second
approach we tested the effect of an enzymatically-inactive tPA
mutant, with the active site Ser478 residue mutated to alanine.
In contrast to tPA, the enzymatically-inactive tPAS478A had no
effect on 5 µM NMDA-mediated changes in calcium levels
(Figures 4A,B).
Inhibition of NMDA-Induced Calcium Influx by
tPA is Independent of Plasmin and LRP-1
To investigate if tPA’s effects on intracellular calcium levels
involved tPA-mediated activation of plasmin, cultures were
preincubated with α2-antiplasmin. α2-antiplasmin (140 nM)
alone did not affect 5 µM NMDA-induced calcium flux and
did not block the effect on tPA on 5 µM NMDA-induced
calcium flux (Figures 5A,B). This suggests that plasmin was not
responsible for the observed tPA response. It does not rule out the
possibility that tPA may be converting plasminogen to plasmin
in our cultures, only that this conversion is not necessary for
the observed effect of tPA on 5 µM NMDA-induced changes
in calcium levels. As tPA has also been proposed to modulate
NMDA-mediated calcium flux through interaction with LRP as
a complex with a specific tPA inhibitor (Martin et al., 2008;
Samson et al., 2008a) experiments were undertaken with the
FIGURE 2 | Calcium responses of cultured hippocampal neurons to high (50 µM) and low (5 µM) concentrations of NMDA are pharmacologically
distinct. Hippocampal cultures were preincubated with antagonists for 15 min before recording calcium responses. Baseline Fluo-4 fluorescence was monitored for
15 s prior to the addition of NMDA (A–C, 50 µM NMDA; E–G, 5 µM NMDA) at time = 0, then monitored for a further 45 s. Raw fluorescence values were converted
to ∆F/F0, where F0 is the average fluorescence over the first 15 s of recording prior to addition of agonist (baseline) and ∆F is Fmax−F0. Antagonists tested were
amino-5-phosphonovalerate (APV) (A,E; 50 µM), MK-801 (B,F; 10 µM); nimodipine (C,G; 10 µM). (D,H) Responses were quantitated by measuring the AUC and are
presented relative to the AUC for 5 µM NMDA (100%). RFU, Relative Fluorescent Units; ∗∗p < 0.005, ∗∗∗p < 0.001. Error bar, SEM.
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FIGURE 3 | tPA inhibits the calcium response of cultured hippocampal
neurons stimulated by presynaptic release of glutamate. Hippocampal
cultures were preincubated with antagonists (15 min) or tPA (5 min). Baseline
Fluo-4 fluorescence was monitored for 15 s prior to the addition of bicucculine
(50 µM) and 4-aminopyridine (4-AP, 250 µM) at time = 0. Fluorescence was
monitored for a further 45 s and values were converted to ∆F/F0, where F0 is
the average fluorescence over the first 15 s of baseline recording. Agents
tested were (A,B) nimodipine (10 µM), (C) tPA (40 µg/ml). (D) Responses
were quantitated by measuring the AUC and are presented relative to the AUC
for 5 µM NMDA (100%). RFU, Relative Fluorescent Units; ∗∗p < 0.005,
∗∗∗p < 0.001. Error bar, SEM.
competitive LRP-1 receptor antagonist RAP. RAP alone had no
effect on NMDA-mediated calcium flux (Figures 5C,D). RAP
also failed to block the inhibitory effect of tPA on NMDA-
mediated calcium flux (Figures 5C,D) suggesting that the tPA-
mediated inhibition of 5 µM NMDA-induced calcium flux does
not involve an interaction with LRP-1 or a similar RAP-sensitive
receptor.
Discussion
In this study we have explored the effect of the proteolytic
enzyme tPA on NMDA receptor-induced calcium flux in
primary cultures of rat hippocampal neurons. Our results reveal
that tPA’s effects on NMDA-mediated changes in intracellular
calcium levels vary with the concentration of NMDA. They
support an inhibitory effect of tPA on calcium flux activated
FIGURE 4 | The proteolytic activity of tPA is required for inhibition of
NMDA-induced calcium influx. (A) Hippocampal cultures were
preincubated with tPA or the enzymatically inactive tPA mutant tPAS478A
(40 µg/ml) for 5 min. Baseline Fluo-4 fluorescence was monitored for 15 s
prior to the addition of NMDA (5 µM), at time = 0. Fluo-4 fluorescence was
monitored for a further 45 s. Raw fluorescence values were converted to
∆F/F0, where F0 is the average fluorescence over the first 15 s of recording
prior to addition of agonist (baseline) and ∆F is Fmax−F0. (B) The responses in
A were quantitated by measuring the AUC and are presented relative to the
AUC for 5 µM NMDA (100%). RFU, Relative Fluorescent Units; n.s, not
significant; ∗∗∗p < 0.001. Error bar, SEM.
by low concentrations of NMDA or synaptic action potentials,
through a mechanism that requires the enzymatic activity of tPA.
We found that pre-treatment of cultured hippocampal
neurons with tPA had no effect on intracellular free calcium
levels following stimulation with 50 µM NMDA. This
relatively high concentration of NMDA has been reported
to directly activate post-synaptic NMDARs (Bading et al.,
1993; Hardingham et al., 2002). Our own results support
this view with NMDA-mediated calcium flux activated by
50 µM NMDA inhibited by NMDA receptor antagonists
but not by an antagonist of voltage-gated calcium channels.
In contrast, tPA pre-treatment inhibited NMDA-stimulated
calcium flux following activation of cultured hippocampal
neurons with 5 µM NMDA. While all NMDARs are expected
to be activated by this lower concentration of NMDA, the
majority of calcium influx in hippocampal neuronal cultures
has been attributed to an NMDA-induced increase in neuronal
firing. Such action potential-induced intracellular calcium
influx is mediated mainly by synaptic NMDARs (Hardingham
et al., 2001a, 2002; Soriano et al., 2006). Our results support
this view with significant inhibition of the calcium response
following antagonism of L-type voltage-gated calcium channels,
which have an established role in synaptically-stimulated
calcium entry (Jensen and Wang, 1996; Wang and Gruenstein,
1997). We further investigated a role for tPA at synaptic
NMDARs by examining its effect on synaptically-evoked bursts
of action potentials. Hippocampal cultures typically contain
approximately 10% inhibitory interneurons that tonically inhibit
the neuronal network. We treated cultures with the GABAA
receptor antagonist bicuculline to relieve this inhibition, leading
to bursts of action potentials and activity-dependent calcium
transients mediated largely by calcium influx through synaptic
NMDA receptor (Hardingham et al., 2001b). Co-treatment with
4-AP, a weak potassium-channel blocker led to elevated calcium
oscillations with ‘‘plateau-type’’ calcium signal (Hardingham
et al., 2002). Pretreatment of these cultures with tPA resulted in
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FIGURE 5 | tPA inhibition of NMDA-induced calcium influx is
independent of plasmin and lipoprotein receptor-related protein 1
(LRP-1). (A) Hippocampal cultures were preincubated with tPA (40 µg/ml; for
5 min) or α2-antiplasmin (140 nM; for 15 min) and tPA (for 5 min). Baseline
Fluo-4 fluorescence was monitored for 15 s prior to the addition of NMDA
(5 µM), at time = 0. Fluo-4 fluorescence was monitored for a further 45 s. Raw
fluorescence values were converted to ∆F/F0, where F0 is the average
fluorescence over the first 15 s of recording prior to addition of agonist
(baseline) and ∆F is Fmax−F0. (B) The responses in A were quantitated by
measuring the AUC and are presented relative to the AUC for 5 µM NMDA
(100%). (C) Hippocampal cultures were preincubated with tPA (40 µg/ml) for
5 min or receptor-associated protein (RAP) (500 nM; for 15 min) and tPA (for
5 min). Baseline Fluo-4 fluorescence was monitored for 15 s prior to the
addition of NMDA (5 µM), at time = 0. Fluo-4 fluorescence was monitored for
a further 45 s. Raw fluorescence values were converted to ∆F/F0, where F0 is
the average fluorescence over the first 15 s of recording prior to addition of
agonist (baseline) and ∆F is Fmax−F0. (D) The responses in C were
quantitated by measuring the AUC and are presented relative to the AUC for
5 µM NMDA (100%). RFU, Relative Fluorescent Units; n.s, not significant;
∗∗∗p < 0.001. Error bar, SEM.
a marked decrease in calcium oscillations, further supporting an
inhibitory effect of tPA on synaptic NMDARs.
To the best of our knowledge this is the first study
to report an inhibitory effect of tPA on NMDA receptor-
mediated calcium flux in neurons. Several other groups have
investigated the effect of tPA on intracellular calcium levels
(Nicole et al., 2001; Reddrop et al., 2005; Samson et al.,
2008b). However in contrast to our results, these studies
reported that tPA potentiated NMDA-mediated calcium levels.
While these studies all involved analyses of mouse cortical
cultures, either as a mixed population of neurons and glial
cells (Nicole et al., 2001) or enriched in neuronal cells
(Reddrop et al., 2005; Samson et al., 2008b), our inhibitory
responses were seen in rat hippocampal cultures cultured
under conditions to enrich for neuronal cells. Glial cells
may influence tPA-mediated responses with tPA recently been
described as a gliotransmitter (Cassé et al., 2012). Another
obvious difference is the concentration of NMDA used across
the different experiments. The tPA inhibitory effects we report
were seen using 5 µM NMDA while the published studies
used concentrations ranging between 25 µM and 100 µM.
The higher concentrations of NMDA would be expected to
result in cellular responses dominated by direct stimulation
of NMDARs whereas the inhibitory effects we observe appear
to be due to trans-synaptic stimulation of synaptic NMDARs.
However, this suggestion alone does not explain why we do
not see a potentiation of NMDA-mediated calcium levels at the
higher NMDA concentrations. The differential effects of tPA
on NMDA-mediated calcium flux could also involve differences
in NMDA receptor subunit composition and differences
in NMDAR responses reflecting association with regulatory
proteins.
Our data support tPA inhibition of NMDA-mediated changes
in calcium levels through a proteolytic mechanism. The changes
could involve direct effects of tPA on the NMDA receptor
to inhibit calcium entry but we cannot exclude changes
in intracellular calcium also involving differential release of
calcium from intracellular stores. Treatment of cultures with
a catalytically inactive tPA mutant did not inhibit NMDA-
mediated calcium flux. tPA has been proposed to cleave the
GluN1 subunit of the NMDA receptor and potentiate NMDA-
induced calcium influx (Nicole et al., 2001; Fernández-Monreal
et al., 2004a; Reddrop et al., 2005; Benchenane et al., 2007).
However, as all NMDARs contain the GluN1 subunit and as
cleavage of this subunit potentiates NMDA-activated levels of
intracellular calcium in neurons, it seems unlikely that the effects
we are seeing are mediated through this subunit. Others have
failed to detect cleavage of the GluN1 subunit of the NMDA
receptor by tPA (Matys and Strickland, 2003; Kvajo et al., 2004;
Liu et al., 2004). There is also evidence that plasmin canmodulate
NMDA receptor function directly (Samson et al., 2008a) or
indirectly (Mannaioni et al., 2008). If plasmin were the functional
unit in our assay conditions we would expect to see relief
of the tPA-mediated inhibition of intracellular calcium levels
when cultures were pre-incubated with the plasmin-specific
inhibitor α2-antiplasmin. While, no such change was observed
(Figures 4A,B), these experiments do not completely exclude a
direct role for plasmin. Future experiments should investigate
the effects of exogenous plasmin on NMDA-mediated calcium
levels.
tPA has also been shown to interact with the NMDA receptor
via the low-density LRP1. Several studies have implicated LRP1
as the major tPA receptor in the brain facilitation subsequent
downstream signaling (Zhuo et al., 2000) and engagement
of the LDLR has been reported to be required for tPA to
influence NMDAR function, including potentiation of NMDA-
mediated calcium influx (Samson et al., 2008a). In these studies
the calcium responses of primary cortical cultures to 25 µM
NMDA were measured before and after a 5 min perfusion
with tPA by video microscopy. tPA was found to enhance
NMDA-mediated calcium influx and the effect was blocked by
the LDLR pan-ligand blocker RAP. Rather than this response
reflecting direct binding of tPA to the LRP receptor, the
authors suggest a model where tPA initially interacts with a
substrate, which they suggest is protease nexin-1 (PN-1), and
a member of the serine protease inhibitor family, and it is
this complex that interacts with the LDLR to activate NMDA
signaling. We saw no significant effect of RAP alone on NMDA-
mediated changes in calcium levels. Moreover, in our assay
conditions, RAP did not block tPA’s inhibitory effect. This may
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suggest that LRP’s main influence on NMDAR function, as
previously reported, is through an interaction with extrasynaptic
NMDARs.
Another potential target of tPA is GluN2D-containing
NMDARs. tPA has been proposed to potentiate GluN2D-
containing NMDA receptor-dependent activation in cortical
neurons activated with 50 µM NMDA with receptor activation
monitored by quantitation of ERK signaling or increased
neuronal death (Baron et al., 2010; Jullienne et al., 2011; Parcq
et al., 2012). Interestingly, tPA was unable to potentiate NMDA-
mediated cell death in hippocampal cultures in this study, even
though NR2D expression is seen in the CA2 region of the
hippocampus. Investigations of tPA’s effect on NMDA-mediated
changes in intracellular calcium levels in cortical cultures should
shed further light on the role of GluN2D-containing NMDARs
and is an important area for future study. Another consideration
is the molecular form of tPA. tPA is secreted as single-chain
tPA but can then undergo cleavage into a two-chain form
by plasmin or kallikrein (Rijken et al., 1982; Rajapakse et al.,
2005). Parcq et al. (2012) recently reported that single-chain
tPA selectively cleaves the NMDA receptor to promote NMDA-
induced calcium influx in mouse embryonic cortical cultures
with two-chain tPA having no effect. Our experiments used
human recombinant tPA (Actilyse) which is 90–95% single-chain
tPA and a recombinant human tPA supplied by Biopur that is
also the single-chain form. They further support an important
role for single-chain tPA as a modulator of NMDAR responses.
Whether two-chain tPA is inactive in our model remains to be
determined.
In conclusion, our study has found that tPA can inhibit
NMDA receptor-mediated changes in intracellular calcium levels
in cultured primary rat embryonic hippocampal neurons when
NMDARs are activated with either low concentrations of
NMDA or through activation of synaptic NMDARs by blocking
GABAA receptor function. These effects require tPA to be
proteolytically active and appear not to involve plasminogen as
a substrate or LRP as part of a receptor-mediated mechanism.
Our data provide additional evidence for the involvement of
tPA in modulating NMDA receptor function and suggest a
further level of complexity to the way that tPA may influence
neuronal physiology and pathology. Further research is needed
to determine which NMDA receptor subtypes are affected and
how the effects relate to hippocampal synaptic plasticity in vivo
(Liu et al., 2004).
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